| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
CNTY-813, an iPSC-derived islet replacement therapy for T1D, presented new nonclinical data at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and remains on track for IND submission in 4Q 2026; initi... |
| 02 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research |
| 09 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
PHILADELPHIA, September 9, 2026 - Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 |
| 16 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 15, 2026, Century Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Employment Agreement (the “A&R Agreement”) with Chad Cowan, Ph.D., the Company’s Chief Scientific Officer. Pursuant to the A&R Agreement, D... |
| 12 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Century Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: |
| 08 Jun 2026 |
8-K: Other Events
CNTY-813: Scalable Production of Allo-Evasion 5.0- Engineered iPSC Islets for Off-the-Shelf Cell Therapies Leonardo Velazco-Cruz, PhD |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 |
| 26 Mar 2026 |
8-K: Other Events
Re: Securities Registered under Registration Statement on Form S-3 |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H ... |
| 23 Jan 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
On January 22, 2026, Century Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). As of November 25, 2025, the record date for the Special Meeting, there were 87,405,311 outstanding shares of... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contai... |
| 08 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 7, 2026 by and among Century Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached here... |
| 29 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Dec 2025 |
8-K: Regulation FD Disclosure
Advancing Pipeline of Transformative Cell Therapies Corporate Deck – December 2025 |
| 09 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
PHILADELPHIA, Dec. 9, 2025 -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the ap... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026 |
| 29 Aug 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 |
| 07 Jul 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation
On July 1, 2025, the Board of Directors (the “Board”) of Century Therapeutics, Inc. (the “Company”) approved a reduction in force as part of a broader effort to right size the organization to focus on programs with the highest potential ... |
Loading...